Country,Population,Intervention,Guideline Comparators,HTA Comparators,Source Types
DE,Patients with Stage IV NSCLC with a KRAS-G12C mutation should be treated acco...,Medicine X (under assessment),Sotorasib,"Patient-individual therapy, taking into account previous ...","Clinical Guideline, Hta Submission"
DK,patients with advanced NSCLC and KRAS G12C mutation previously treated with p...,Medicine X (under assessment),"adagrasib, docetaxel, sotorasib","docetaxel monotherapy, standard of care therapy","Clinical Guideline, Hta Submission"
EN,KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lun...,Medicine X (under assessment),"docetaxel, docetaxel plus nintedanib","docetaxel, docetaxel plus nintedanib","Clinical Guideline, Hta Submission"
EU,treatment of patients with advanced non-small cell lung cancer (NSCLC) with K...,Medicine X (under assessment),,-,Clinical Guideline
FR,adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC)...,Medicine X (under assessment),adagrasib,"chemotherapists in the single line: pemetrexed, docetaxel...","Clinical Guideline, Hta Submission"
PT,adult patients with advanced non-small cell lung cancer (NSCLC) with mutated ...,Medicine X (under assessment),-,"atezolizumab, docetaxel, docetaxel + nintedanib, nivoluma...",Hta Submission
SE,patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C ...,Medicine X (under assessment),,"best supportive care, docetaxel","Clinical Guideline, Hta Submission"
